Sort
25,944 grants matching “neurodegeneration”
Novel Inducible Complement C3 Conditional KO Mouse Models to Investigate Neurodegeneration in AD
$3,441,150Cynthia A Lemere · Brigham And Women'S Hospital · RF1 · FY2018 · AG
PET Radiopharmaceutical Sciences
$3,432,364Victor W Pike · National Institute Of Mental Health · ZIA · FY2012 · MH
Offspring Study of Mechanisms for Racial Disparities in Alzheimer's Disease
$3,429,627Jennifer Jaie Manly · Columbia University Health Sciences · R01 · FY2021 · AG
New mechanistic insights into how the gut metabolite urolithin A extends lifespan and prevents AD
$3,414,407Julie Kay Andersen · Buck Institute For Research On Aging · RF1 · FY2018 · AG
UCSD Alzheimer's Disease Research Center P50
$3,411,971James B Brewer · University Of California, San Diego · P50 · FY2017 · AG
UCSD Alzheimer's Disease Research Center P50
$3,410,711James B Brewer · University Of California, San Diego · P50 · FY2018 · AG
Age-Associated Modulation of Gene Expression in the CNS
$3,394,232Henryk F Urbanski · Oregon Health & Science University · RF1 · FY2018 · AG
Diabetes and brain amyloid in middle aged Hispanics
$3,379,069Jose A Luchsinger · Columbia University Health Sciences · R01 · FY2025 · AG
Offspring Study of Mechanisms for Racial Disparities in Alzheimer's Disease
$3,375,124Jennifer Jaie Manly · Columbia University Health Sciences · R01 · FY2022 · AG
Offspring Study of Mechanisms for Racial Disparities in Alzheimer's Disease
$3,374,719Jennifer Jaie Manly · Columbia University Health Sciences · R01 · FY2024 · AG
Offspring Study of Mechanisms for Racial Disparities in Alzheimer's Disease
$3,374,719Jennifer Jaie Manly · Columbia University Health Sciences · R01 · FY2023 · AG
Molecular Regulation of AEP during Ageing
$3,370,029Keqiang Ye · Emory University · RF1 · FY2016 · AG
PET Radiopharmaceutical Sciences
$3,368,404Victor W Pike · National Institute Of Mental Health · ZIA · FY2015 · MH
Massachusetts Alzheimer's Disease Research Center
$3,361,193Bradley T Hyman · Massachusetts General Hospital · P30 · FY2021 · AG
Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs.
$3,360,074James Shorter · University Of Pennsylvania · RF1 · FY2025 · AG
The Longitudinal Course of Imaging Biomarkers in People At Risk for Alzheimerâs Disease
$3,356,853Sterling C Johnson · University Of Wisconsin-Madison · R01 · FY2025 · AG
A systems biology approach in Drosophila to identify novel factors that influence AD pathogenicity
$3,354,976Daniel Edward Lee Promislow · University Of Washington · RF1 · FY2017 · AG
Regulated cGAS activation in HSV-1-associated neuropathogenesis.
$3,354,022Pinghui Feng · University Of Southern California · RF1 · FY2025 · AG
Inflammation and Renin-Angiotensin System Dysfunction as risk factors for AD
$3,352,237Whitney Lee Wharton · Emory University · RF1 · FY2015 · AG
Small Molecule Ligands Targeting Pathological Tau Signaling In AD And Related Dementias
$3,336,256Scott Thomas Brady · University Of Illinois At Chicago · RF1 · FY2025 · AG
PET Radiopharmaceutical Sciences
$3,330,051Victor W Pike · National Institute Of Mental Health · ZIA · FY2011 · MH
Humanin is an AD resilience factor through its interaction with APOE4
$3,327,055Pinchas Cohen · University Of Southern California · RF1 · FY2018 · AG
Investigating aberrant vesicular degradation and lipid metabolism in neurodegeneration
$3,323,710Daryl A Bosco · Univ Of Massachusetts Med Sch Worcester · RF1 · FY2025 · NS
Vanderbilt Memory & Aging Project
$3,318,775Angela L. Jefferson · Vanderbilt University Medical Center · R01 · FY2025 · AG
Longitudinal Study of Cognitive and Biological Aging in Midlife and Older Sexual and Gender Minority Adults
$3,314,261Tara McKay · Vanderbilt University · RF1 · FY2025 · AG